Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...

This was the stock's third consecutive day of losses.

Shares of Pfizer Inc. PFE slid 1.82% to $23.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to 5,888.55 and Dow ...

Pfizer's stock performance has been far from thrilling this year, with shares down 3.87% year-to-date. In contrast, the S&P 500 has surged over 21%, making Pfizer look like the laggard of the pack.

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Per the updated projection for next year, the business anticipates ...